Showing results (1-10 of 40) with videos related to
Sort By:
Pageof 4
Antibodies (Basel, Switzerland)|October 25, 2024
Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future DirectionsKinsley Wang, Robert HsuJournal of the American College of Emergency Physicians Open|May 4, 2022
Acute aortic occlusion associated with COVID-19: A rare complication of a not so rare diseaseRyan Lee, Robert HsuFrontiers in Immunology|September 7, 2023
Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapyDavid J Benjamin, Robert HsuFrontiers in Oncology|December 18, 2023
A narrative review of antibody-drug conjugates in EGFR-mutated non-small cell lung cancerRobert Hsu, David J BenjaminAntibodies (Basel, Switzerland)|January 21, 2026
Updates on Antibody Drug Conjugates and Bispecific T-Cell Engagers in SCLCKinsley Wang, Kyle Taing, Robert HsuExploration of Targeted Anti-Tumor Therapy|January 6, 2025
Addressing the unmet need in NSCLC progression with advances in second-line therapeuticsKinsley Wang, Alexis Leyba, Robert HsuCancers|July 28, 2026
Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative ReviewKyle Taing, Hei Yeung Lam, Robert HsuCancers|July 29, 2023
The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative ReviewRobert Hsu, David J Benjamin, Misako NagasakaCancer Drug Resistance (Alhambra, Calif.)|June 5, 2024
ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategiesDarin Poei, Sana Ali, Shirley Ye, et al.Research Square|November 1, 2024
Assessing platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: An analysis across TKI generationsRyan Cooper, Dhruv Ramaswami, Jacob Thomas, et al.Pageof 4